天津医药

天津医药 ›› 2018, Vol. 46 ›› Issue (9): 937-941.doi: 10.11958/20180244

• 临床研究 • 上一篇    下一篇

高迁移率族警报素的表达在非小细胞肺癌患者预后中的意义

刘婷，赵华，魏枫，王扬，任秀宝   

  1. 天津医科大学肿瘤医院生物技术研究室，国家肿瘤临床医学研究中心，天津市肿瘤免疫与生物治疗重点实验室，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心（邮编300060）
  • 收稿日期:2018-02-12 修回日期:2018-06-06 出版日期:2018-09-15 发布日期:2018-10-10
  • 通讯作者: 任秀宝 E-mail:renxiubao@tjmuch.com

The significance of high-mobility group alarmins expression in the prognosis of NSCLC patients

LIU Ting, ZHAO Hua, WEI Feng, WANG Yang, REN Xiu-bao   

  1. Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China
  • Received:2018-02-12 Revised:2018-06-06 Published:2018-09-15 Online:2018-10-10

PDF (PC)

3881

摘要： 目的 探讨高迁移率蛋白B1和N1（HMGN1和HMGB1）与非小细胞肺癌（NSCLC）临床病理特征及预后的相关性。方法 采用免疫组织化学染色（IHC）方法检测 91 例 NSCLC 患者的肿瘤组织石蜡标本胞浆中 HMGB1 和HMGN1的表达情况，计算阳性表达率。分析HMGB1和HMGN1的表达与临床病理特征相关性。利用Kaplan-Meier法分析HMGB1和HMGN1与预后的关系。结果 91例患者中HMGB1和HMGN1细胞胞浆的阳性表达率分别为40%（36/91）和31%（28/91），两者表达水平呈正相关（rs=0.319，P＜0.001）。晚期NSCLC（Ⅲ~Ⅳ期）的HMGN1阳性表达率高于早期NSCLC（Ⅰ~Ⅱ期）患者（P＜0.05）。有淋巴结转移者HMGN1的阳性表达率高于无淋巴结转移者（P＜0.05）；HMGN1高表达的NSCLC患者预后稍劣于低表达者，但差异无统计学意义。结论 HMGN1可能成为一种预测非小细胞肺癌预后的生物标志物。

关键词: 癌, 非小细胞肺, 肿瘤分期, 预后, 高迁移率蛋白B1, 高迁移率蛋白N1, 标志物

Abstract: Objective To explore the relationship between expressions of high mobility group B1 and N1(HMGB1 and HMGN1) and clinical pathological parameters and prognosis in patients with non-small cell lung cancer (NSCLC). Methods Ninety-one postoperative tumor tissue specimens from the patients with NSCLC were collected in Tianjin Medical University Cancer Institute and Hospital from January 2004 to May 2011. Immune histochemical assay was used to detect the expressions of HMGB1 and HMGN1. According to the staining intensity, expressions of HMGB1 and HMGN1 were divided into positive and negative groups. Kaplan-Meier was used to analyze the correlation between the expressions of HMGB1/HMGN1 and clinical pathological parameters/prognosis. Results The cytoplasmic expressions of HMGB1 (40%,36/91) was positively correlated with cytoplasmic expression of HMGN1 (31%, 28/91, rs=0.319，P<0.001). The expression level of HMGN1 was significantly higher in patients with late stage of NSCLC (Ⅲ~Ⅳ) than that in patients with early stage of NSCLC (Ⅰ~Ⅱ, P＜0.05). It was also found that the expression level of HMGN1 was significantly higher in patients with lymph node metastasis than that in patients without lymph node metastasis (P＜0.05). The poor prognosis of NSCLC was slightly lower in patients with high expression of HMGN1 than that in patients with low expression of HMGN1, but the difference was not statistically significant. Conclusion The HMGN1 can be used as a promising prognostic biomarker for predicting the prognosis of NSCLC patients.

Key words: carcinoma, non-small-cell lung, neoplasm staging, prognosis, high mobility protein B1, high mobility protein N1, biomarker